scholarly journals Complete Genome Sequence of Proteus mirabilis Siphophage Saba

2019 ◽  
Vol 8 (41) ◽  
Author(s):  
James Nguyen ◽  
Laith Harb ◽  
Russell Moreland ◽  
Mei Liu ◽  
Jason J. Gill ◽  
...  

Proteus mirabilis is a Gram-negative enteric bacterium associated with complicated human urinary tract infections. Here, we present the complete genome annotation for P. mirabilis siphophage Saba. With a 60,056-bp genome and 75 predicted genes, Saba is most similar at the nucleotide and protein levels to phage Chi and Chi-like viruses.

2019 ◽  
Vol 8 (47) ◽  
Author(s):  
Jennifer Tran ◽  
Lauren Lessor ◽  
Chandler O’Leary ◽  
Jason Gill ◽  
Mei Liu

Proteus mirabilis as a nosocomial pathogen is often the cause of urinary tract infections. This announcement describes the complete genome sequence of a P. mirabilis myophage named Myduc. Phage Myduc is related to Enterobacteria phage phiEcoM-GJ1, which belongs to a group of myophages with small genome sizes (52,000 to 56,000 bp) possessing a T7-like RNA polymerase.


2017 ◽  
Vol 61 (8) ◽  
Author(s):  
Nayara Helisandra Fedrigo ◽  
Josmar Mazucheli ◽  
James Albiero ◽  
Danielle Rosani Shinohara ◽  
Fernanda Gomes Lodi ◽  
...  

ABSTRACT Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gram-negative bacterial isolates, consisting of 158 Escherichia coli isolates and 87 Klebsiella isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against E. coli (MIC90 ≤ 16 μg/ml) but not against Klebsiella spp. (MIC90 > 512 μg/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an E. coli isolate with an MIC of ≤64 mg/liter was able to achieve a PTA of ≥90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against E. coli and Klebsiella spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both E. coli and Klebsiella isolates.


2015 ◽  
Vol 3 (5) ◽  
Author(s):  
Jingwen Guan ◽  
Jeffrey D. Snowden ◽  
Jesse L. Cahill ◽  
Eric S. Rasche ◽  
Gabriel F. Kuty Everett

Citrobacter freundiiis a Gram-negative opportunistic pathogen that is associated with urinary tract infections. Bacteriophages infectingC. freundiican be used as an effective treatment to fight these infections. Here, we announce the complete genome sequence of theC. freundiiFelix O1-like myophage Mordin and describe its features.


2019 ◽  
Vol 8 (43) ◽  
Author(s):  
Taylor A. Bourgeois ◽  
Lauren Lessor ◽  
Chandler O’Leary ◽  
Rohit Kongari ◽  
Mei Liu

Proteus mirabilis, a Gram-negative bacterium belonging to the family Enterobacteriaceae, is a common cause of urinary tract infections. Phages infecting Proteus mirabilis could be used as therapeutics to treat infections caused by this bacterium. This announcement describes the complete genome sequence of the T5-like P. mirabilis phage Stubb.


2017 ◽  
Vol 5 (18) ◽  
Author(s):  
Kurosh S. Mehershahi ◽  
Swaine L. Chen

ABSTRACT Escherichia coli is the most common bacterium causing urinary tract infections in humans. We report here the complete genome sequence of the uropathogenic Escherichia coli strain NU14, a clinical pyelonephritis isolate used for studying pathogenesis.


2017 ◽  
Vol 62 (1) ◽  
Author(s):  
William J. Weiss ◽  
Mark E. Pulse ◽  
Phung Nguyen ◽  
Kelly Peterson ◽  
Jessica Silva ◽  
...  

ABSTRACT The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPC-producing, carbapenem-resistant Enterobacteriaceae.


2016 ◽  
Vol 60 (7) ◽  
pp. 4355-4360 ◽  
Author(s):  
Helio S. Sader ◽  
Mariana Castanheira ◽  
Robert K. Flamm ◽  
Ronald N. Jones

ABSTRACTA total of 7,272 unique patient clinical isolates were collected from 71 U.S. medical centers from patients with urinary tract infections in 2012 to 2014 and tested for susceptibility to ceftazidime-avibactam and comparators by broth microdilution methods. Ceftazidime-avibactam inhibited >99.9% of allEnterobacteriaceaeat the susceptible breakpoint of ≤8 μg/ml (there were only three nonsusceptible strains). Ceftazidime-avibactam was also active againstPseudomonas aeruginosaisolates (MIC50, 2 μg/ml; MIC90, 4 μg/ml; 97.7% susceptible), including many isolates not susceptible to meropenem, ceftazidime, and/or piperacillin-tazobactam.


Sign in / Sign up

Export Citation Format

Share Document